PMGC Holdings Inc. (ELAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28M
Last updated: Nov 17, 2026 at 11:04 AM ET
PMGC Holdings Inc. (ELAB) Financials: Revenue, Profit and Cash Flow
PMGC Holdings reported revenue of $590.08K for the fiscal year ended Dec 31, 2025. That year, net income was -$7.75M with a net margin of -1313.0%, operating cash flow was -$5.93M and free cash flow was -$6.38M. The quarter ended Sep 30, 2026 had revenue of $2.53M and net income of -$2.24M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $590.08K | N/A | 31.4% | -1034.4% | -1313.0% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $766.28K | +92557.4% | 58.4% | -233.4% | -234.9% |
| Dec 2021 | $827 | N/A | -244.0% | -94928.7% | -94889.8% |
| Dec 2020 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | $590.08K | $0 | $0 | $766.28K | $827 | N/A |
| Cost of revenue | $404.77K | $0 | $0 | $318.97K | $2.85K | N/A |
| Gross profit | $185.31K | $0 | $0 | $447.31K | -$2.02K | N/A |
| Research and development | $147.01K | $104.65K | $7.41K | $228.75K | $123.63K | $118.86K |
| Operating income | -$6.10M | -$3.66M | -$1.13M | -$1.79M | -$785.06K | -$221.84K |
| Net income | -$7.75M | -$6.25M | -$4.30M | -$1.80M | -$784.74K | -$222.91K |
| EBITDA | -$5.80M | -$3.28M | N/A | N/A | -$782.30K | -$1.07K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53M | $1.31M | $681.99K | $18.19K | $285.95K | $0 | $0 | -$1.75M | $0 | $0 | $0 | -$1.01M |
| Gross profit | $601.44K | $385.69K | $230.47K | $107.28K | $78.03K | $0 | $0 | -$1.75M | $0 | $0 | $0 | -$672.88K |
| Operating income | -$2.48M | -$3.71M | -$3.32M | -$1.82M | -$2.20M | -$1.01M | -$1.07M | -$1.68M | -$625.62K | -$556.05K | -$798.18K | $1.55M |
| Net income | -$2.24M | -$2.94M | -$4.97M | -$3.33M | -$2.59M | -$562.36K | -$1.61M | -$1.93M | -$1.50M | -$1.41M | -$1.40M | -$1.16M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $1.42M by $3.98M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Total assets | $12.87M | $8.99M | $5.19M | $1.89M | $666.25K | $17.02K |
| Current assets | $6.87M | $6.05M | $4.92M | $1.55M | $636.52K | $17.02K |
| Cash and equivalents | $5.40M | $3.98M | $3.33M | $1.15M | $411.86K | $13.35K |
| Total liabilities | $5.03M | $2.33M | $1.36M | $760.87K | $215.62K | $40.61K |
| Short-term debt | $1.34M | $0 | $145.00K | $110.62K | N/A | $24.00K |
| Long-term debt | $85.00K | $0 | N/A | N/A | N/A | N/A |
| Shareholder equity | $7.84M | $6.66M | $3.83M | $1.13M | $450.63K | -$23.59K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $133.10M | $36.56M | $26.03M | $12.87M | $14.94M | $9.38M | $8.89M | $8.99M | $11.21M | $5.08M | $4.23M | $5.19M |
| Total liabilities | $21.03M | $19.83M | $13.43M | $5.03M | $6.45M | $326.30K | $760.27K | $2.33M | $2.65M | $2.44M | $1.74M | $1.36M |
| Cash and equivalents | $12.98M | $18.14M | $14.35M | $5.40M | $7.70M | $5.68M | $5.36M | $3.98M | $6.43M | $100.03K | $943.80K | $3.33M |
| Shareholder equity | $12.11M | $16.74M | $12.61M | $7.84M | $8.49M | $9.05M | $8.13M | $6.66M | $8.56M | $2.64M | $2.49M | $3.83M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.93M | -$5.49M | -$4.56M | -$1.59M | -$660.93K | -$217.16K |
| Capital expenditures | $442.25K | $9.16K | $11.19K | $35.53K | $32.48K | $0 |
| Free cash flow | -$6.38M | -$5.50M | -$4.57M | -$1.62M | -$693.42K | -$217.16K |
| Share repurchases | $179 | $0 | N/A | $0 | N/A | N/A |
| Investing cash flow | -$2.77M | -$610.56K | -$11.19K | -$32.03K | -$32.48K | N/A |
| Financing cash flow | $10.12M | $6.76M | $6.74M | $2.36M | $1.09M | $238.28K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.26M | -$1.99M | -$2.98M | -$1.75M | -$1.49M | -$1.35M | -$1.35M | -$2.00M | -$381.68K | -$780.69K | -$2.32M | -$2.39M |
| Capital expenditures | $361.43K | $27.57K | $363.09K | $346.66K | $95.59K | $2 | $0 | $300.00K | $50.00K | $62.32K | $9.16K | $59.16K |
| Free cash flow | -$2.62M | -$2.02M | -$3.34M | -$2.10M | -$1.59M | -$1.35M | -$1.35M | -$2.30M | -$431.68K | -$843.01K | -$2.33M | -$2.45M |
Frequently Asked Questions About ELAB
What is PMGC Holdings' annual revenue?
PMGC Holdings reported revenue of $590.08K for the fiscal year ended Dec 31, 2025.
Is PMGC Holdings profitable?
No. PMGC Holdings reported net income of -$7.75M for the fiscal year ended Dec 31, 2025, with a net margin of -1313.0%.
How much free cash flow does ELAB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.93M minus capital expenditures of $442.25K produced free cash flow of -$6.38M.
How much debt does PMGC Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $85.00K, short-term debt of $1.34M and cash and equivalents of $5.40M.
What is ELAB's profit margin?
For the fiscal year ended Dec 31, 2025, PMGC Holdings reported gross margin of 31.4%, operating margin of -1034.4% and net margin of -1313.0%.
ELAB pages: Overview, Financials, Valuation, Competitors